

March 22, 2024  
Symbio Pharmaceuticals Limited  
Fuminori Yoshida  
Representative Director  
President & Chief Executive Officer  
(Securities Code: 4582)

## Notice of Appointments to the Board Directors and substitute member of the Audit & Supervisory Committee, and Appointments of Corporate Officers

TOKYO, Japan, March 22, 2024 - Symbio Pharmaceuticals Limited (Headquarters: Tokyo) today announced appointments to its Board Directors (excluding directors who are members of the Audit & Supervisory Committee), Board of Directors who are members of the Audit & Supervisory Committee and one substitute member of the Audit & Supervisory Committee made by resolution of shareholders approved at the 19th Annual General Meeting of Shareholders (the “AGM”), and Representative Director and Corporate Officer appointments approved by the Board of Directors at a board meeting convened following the close of the AGM. The appointments are as follows:

1. Board Directors (excluding directors who are Audit and Supervisory Committee members)

Name	Title
Fuminori Yoshida	Representative Director
Shigetoshi Matsumoto	Board Director <Outside>
Bruce David Cheson	Board Director <Outside>
Eiji Ebinuma	Board Director <Outside>
Toshio Imabeppu (newly appointed)	Board Director <Outside>
George Morstyn (newly appointed)	Board Director <Outside>

2. Board Directors who are members of the Audit & Supervisory Committee

Name	Title
Kiyoshi Watanabe	Board Director, Full-Time Audit & Supervisory Committee Member <Outside>
Kesao Endo	Board Director, Audit & Supervisory Committee Member <Outside>
Yasuhiro Tamou	Board Director, Audit & Supervisory Committee Member <Outside>

3. Substitute Member of the Audit & Supervisory Committee

Name	Title
Takashi Watanabe	Substitute Member of the Audit & Supervisory Committee <Outside>

#### 4. Corporate Officers

Name	Title
Fuminori Yoshida	President and Chief Executive Officer
Takaaki Fukushima	Executive Vice President, Corporate Officer, Chief Financial Officer
Shunichi Sasaki (newly appointed)	Executive Corporate Officer
Hiroyuki Horita	Corporate Officer

The biographies of the two new directors and a corporate officer are as follows:

New Director	Toshio Imabeppu	
Career	Apr., 1981	Entered Ministry of Health and Welfare (currently Ministry of Health, Labor and Welfare)
	Oct., 1988	Office of Advanced Pharmaceutical Technology Promotion, Ministry of Health, Labour and Welfare
	Aug., 2002	Cabinet Counselor, Cabinet Secretariat
	Jul., 2004	Director, Insurance Division, Ministry of Health, Labour and Welfare
	Jul., 2008	Director, Accounting Division, Ministry of Finance
	Jul., 2013	Director General, Pharmaceutical and Food Safety Bureau, Ministry of Health, Labour and Welfare
	Jul., 2014	Director for Policy Management, Ministry of Foreign Affairs of Japan
	Oct., 2015	retirement from MHLW
	Jun., 2019	Outside Director of Ship Healthcare Holdings HD (concurrent)
	Jun., 2022	Chairman of the Board of Directors, Japan Association for Regenerative Medicine (concurrent)
	Jun., 2022	Representative Director, Judo Therapy Training and Examination Foundation (concurrent)
	Mar., 2024	Symbio Pharmaceuticals Outside Director

New Director	George Morstyn	
Career	Mar., 1991	Senior Vice President, Global Development and CMO, Amgen Inc.
	Apr., 2006	CEO, G&R Morstyn Party Limited (concurrent)
	Mar., 2009	Appointed as Symbio Pharmaceuticals Outside Director
	Jul., 2010	Vice Chair, Victorian Comprehensive Cancer Centre, Australia

Dec., 2017	External Director of Actinogen Medical (Australia) Pty Ltd (concurrent)
Mar., 2019	Resignation from SymBio Pharmaceuticals Outside Director
May, 2021	Chairman of the Board of Directors, PioTx, Australia (concurrent)
Mar., 2024	SymBio Pharmaceuticals Outside Director

New Corporate Officer		Shunichi Sasaki
Career	Mar., 1996	Tokyo University of Pharmacy and Life Science (Chemistry)
	Mar., 1998	Graduate School Tokyo University of Pharmacy and Life Science Graduated with Master of Science
	Apr., 1998	DAIICHI PHARMACEUTICAL CO., LTD. PL/ APL/ CRA, Clinical Development, R&D Division
	Nov., 2006	Associate Director, Clinical Development, DAIICHI SANKYO PHARMA DEVELOPMENT, USA (seconded)
	Mar., 2009	Ph.D at Tokyo Medical University
	Jun., 2011	DAIICHI SANKYO CO., LTD. TOKYO Associate Director, Clinical Development I, R&D Division
	Oct., 2012	Associate Director, Clinical Development, DAIICHI SANKYO PHARMA DEVELOPMENT, USA(CVM) (seconded)
	Feb., 2015	Associate Director, Clinical Development, DAIICHI SANKYO PHARMA DEVELOPMENT, USA(Oncology) (seconded)
	Oct., 2015	DAIICHI SANKYO CO., LTD. TOKYO Associate Director, Asia Development Department, Clinical Group (Oncology)
	Apr., 2019	Senior Director, Asia Development Department, Clinical Development Group
	Apr., 2020	Senior Director/Group Leader, Clinical Development Department 1, Group 2
	Dec., 2021	Resigned from DAIICHI SANKYO CO., LTD. TOKYO
	Jan., 2022	GE Healthcare Pharma CO., LTD. TOKYO Head of Clinical Development Japan

Dec., 2023	Resigned from GE Healthcare Pharma CO., LTD. TOKYO
Jan., 2024	Joined SymBio, Head of Japan Development Division
Feb., 2024	Head of Japan Development Division and Co-Head of Global BCV Business Unit
Mar., 2024	Executive Corporate Officer, Head of Japan Development Division and Co-Head of Global BCV Business Unit

**[Contact]**

Investor Relations

Tel: +81(0)3 5472 1125